Galmed Pharmaceuticals annual stock-based compensation
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Galmed Pharmaceuticals Stock-Based Compensation Growth & History (GLMD)
Galmed Pharmaceuticals's stock-based compensation was $546,000 for fiscal 2025.
View full Galmed Pharmaceuticals company overviewGalmed Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $546,000 | $15,000 | +2.82% |
| 2024 | 2024-12-31 | $531,000 | −$361,000 | −40.47% |
| 2023 | 2023-12-31 | $892,000 | −$404,000 | −31.17% |
| 2022 | 2022-12-31 | $1.3M | −$590,000 | −31.28% |
| 2021 | 2021-12-31 | $1.9M | −$180,000 | −8.71% |
| 2020 | 2020-12-31 | $2.1M | −$165,000 | −7.40% |
| 2019 | 2019-12-31 | $2.2M | $448,000 | +25.13% |
| 2018 | 2018-12-31 | $1.8M | $389,000 | +27.91% |
| 2017 | 2017-12-31 | $1.4M | −$234,000 | −14.37% |
| 2016 | 2016-12-31 | $1.6M | $658,000 | +67.84% |
| 2015 | 2015-12-31 | $970,000 | $369,000 | +61.40% |
| 2014 | 2014-12-31 | $601,000 | −$10.3M | −94.46% |
| 2013 | 2013-12-31 | $10.9M | $10.6M | +5116.83% |
| 2012 | 2012-12-31 | $208,000 | — | — |
Galmed Pharmaceuticals quarterly stock-based compensation
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $156,000 | $56,000 | +56.00% |
| Q1 2026 | 2026-03-31 | $156,000 | $55,000 | +54.46% |
| Q4 2025 | 2025-12-31 | $240,000 | — | — |
| Q3 2025 | 2025-09-30 | $105,000 | −$27,000 | −20.45% |
| Q2 2025 | 2025-06-30 | $100,000 | — | — |
| Q1 2025 | 2025-03-31 | $101,000 | — | — |
| Q3 2024 | 2024-09-30 | $132,000 | — | — |
Galmed Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, Galmed Pharmaceuticals's stock-based compensation decreased from $2.1M to $546,000, a change of −$1.5M. The latest reported quarter, Q2 2026, shows $156,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Galmed Pharmaceuticals source filings ↗